文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌后发生异时性上尿路尿路上皮癌的风险

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-11-19

这项多中心回顾性队列研究纳入2005至2022年治疗的3003例非肌层浸润性膀胱癌患者,评估异时性上尿路尿路上皮癌的风险与时机。中位随访4.9年,104例发生UTUC,10年累积发生率低危2.2%、中危4.4%、高危和极高危6.3%;多变量分析显示多发肿瘤为独立预测因子。结论支持低危患者省略常规上尿路影像,中危患者影像效用存疑,高危患者仍需常规影像。

要点

  • 低危及中危NMIBC患者UTUC发生率低,支持指南省略低危患者常规上尿路影像。
  • 高危和极高危患者10年UTUC累积发生率为6.3%,常规影像仍必要。
  • 多发肿瘤是UTUC独立预测因子(SHR 1.86,95%CI 1.24-2.80;P=0.003)。

核心结论

  • 当代异时性UTUC风险可能低于历史数据,低危和中危NMIBC患者UTUC发生率低,高危和极高危组升高。
  • 结果支持当前指南推荐:低危NMIBC省略常规上尿路影像,中危患者影像效用存疑,高危患者仍需常规影像。

研究设计与样本

  • 多中心回顾性队列研究,纳入学术和社区医院2005至2022年治疗的NMIBC患者,排除诊断时已有或同时性UTUC者,共3003例。
  • 主要结局为经病理或上尿路影像证实的异时性UTUC时间,采用Fine和Gray回归(全因死亡为竞争风险)分析危险因素。

主要发现

  • 中位随访4.9(IQR 2.7-8.4)年,104例发生UTUC。
  • 多变量分析显示多发肿瘤为UTUC独立预测因子(SHR 1.86,95%CI 1.24-2.80;P=0.003)。
  • 10年累积发生率:低危2.2%,中危4.4%,高危和极高危6.3%。
  • 常规影像检出UTUC的比例:低危40%,中危58%,高危和极高危53%。
  • 高级别UTUC比例:低危36%,中危63%,高危和极高危64%;77%的UTUC发生在NMIBC后5年内。

关键数值与推荐

  • 风险分组:低危1158例(39%),中危650例(22%),高危944例(31%),极高危251例(8%)。
  • 10年UTUC累积发生率低危2.2%、中危4.4%、高危和极高危6.3%。
  • 多发肿瘤的SHR为1.86(95%CI 1.24-2.80;P=0.003)。

临床怎么用

  • 低危NMIBC患者可省略常规上尿路影像。
  • 中危NMIBC患者常规上尿路影像的效用存疑。
  • 高危NMIBC患者仍需常规上尿路影像,但最佳频率和持续时间尚未确定。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 高危患者常规影像的最佳频率和持续时间尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the risk and timing of metachronous upper tract urothelial carcinoma (UTUC) after non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: In this multi-institutional retrospective cohort study involving academic and community hospitals, clinicopathological data were collected from patients with NMIBC treated between 2005 and 2022. Patients with prior or synchronous UTUC at NMIBC diagnosis were excluded. The primary outcome was time to metachronous UTUC, confirmed on pathology or upper tract imaging. Secondary objectives included determining the cumulative incidence of UTUC stratified by the European Association of Urology risk groups and UTUC risk factors identified using Fine and Gray regression, with all-cause mortality as a competing risk. RESULTS: Among 3003 patients, 1158 (39%) were low-risk, 650 (22%) intermediate-risk, 944 (31%) high-risk, and 251 (8%) very high-risk. During a median (interquartile range) follow-up of 4.9 (2.7-8.4) years, 104 patients developed UTUC. On multivariable analysis, multiple tumours were an independent predictor of UTUC (subdistribution hazard ratio 1.86, 95% confidence interval 1.24-2.80; P = 0.003). The 10-year cumulative incidence was 2.2% for low-risk, 4.4% for intermediate-risk, and 6.3% for high- and very high-risk patients. Routine imaging detected UTUC in 40% of low-risk, 58% of intermediate-risk, and 53% of high- and very high-risk patients. High-grade UTUC was found in 36% of low-risk, 63% of intermediate-risk, and 64% of high- and very high-risk patients. The majority of UTUC cases (77%) occurred within 5 years of NMIBC. CONCLUSIONS: The contemporary risk of metachronous UTUC may be lower than historical data. Our findings demonstrate that UTUC incidence is low in patients with low- and intermediate-risk NMIBC and increases in the high- and very high-risk groups. These results support current guideline recommendations to omit routine upper tract imaging in low-risk NMIBC and question its utility in intermediate-risk disease. In high-risk patients, routine imaging remains warranted, although the optimal frequency and duration are yet to be determined.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Pace KJC, Kwong JCC, Randhawa H, et al. Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 41260885. doi:10.1111/bju.70085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。